About Abbocan

Abbocan advances next-generation veterinary therapeutics globall through its proprietary synthetic biology and bioenzyme-based advanced manufacturing platforms. We develop precision alternatives to conventional treatments, prioritizing high-end ornamental aquaculture, premium aquaculture species, and companion animals—with safety, efficacy, and environmental stewardship at the core.

Our approach integrates rigorous scientific validation with strategic regulatory engagement. We collaborate proactively with regulatory bodies to establish compliant pathways for therapeutics addressing unmet health needs while maintaining environmental standards.

We target professional veterinary channels seeking therapeutics backed by scientific rigor and regulatory clarity, and proven efficacy and safety. Our pipeline: ornamental aquaculture, premium aquaculture, and companion animals, each supported by scale-up validation and distribution partnership development.

At GPE 2026, we seek strategic partnerships with distribution leaders, capital partners, and collaborators who recognize the substantial market opportunity and share our commitment to advancing global animal health through sustainable, professionally delivered therapeutics.

Innovation in Animal Health. Sustainability by Design.

ABC-2: Next-Generation Deworming Solution

ABC-2 is our lead candidate—a precision-engineered deworming solution for hobbyists, professional aquaculture, and specialty veterinary channels. Unlike legacy treatments, ABC-2 meets pharmaceutical-grade safety, efficacy, and manufacturing standards.

Key Advantages:

Precision Formulation: Advanced formulation and production optimization across varied aquatic environments—critical for professional operations and high-value collections.

Pharmaceutical Integrity: Maximizes efficacy while minimizing toxicity and environmental impact—supporting regulatory compliance and practitioner confidence.

Simplified Administration: Streamlined dosing reduces user error—enabling rapid adoption by ornamental fish enthusiasts, retailers, clinics, and experienced aquarists.

Regulatory Momentum: Strategic engagements underway to establish compliant pathways. Positioned for accelerated market entry through frameworks optimized for minor species and specialty aquaculture.

Target Market

Strategic entry through regulatory-compliant ornamental fish therapeutics— professional credentials and distribution infrastructure before scaling to larger markets.

Multi-Species Expansion Platform

Abbocan is a scalable therapeutic platform balancing near-term revenue with long-term value across multiple high-value animal health segments.

Phase 1(2026-2028): Ornamental aquaculture commercialization establishes regulatory credentials, distribution networks, and brand authority—enabling scale-up with proven efficacy, safety, and product quality.
Phase 2(2028-2030): Premium food-chain aquaculture addresses food security, leveraging Phase 1 pathways. Unlocks volume-based growth in underserved markets.
Phase 3(2030+): Companion animals (canine, feline, horse) and strategic human health collaborations demonstrate platform versatility and institutional partnership opportunities.

Total TAM: $330+ billion globally, with high-end ornamental aquaculture as strategic entry to capture professional loyalty before scaling into other higher-volume segments.

Strategic Objectives at GPE 2026

Building Partnerships & Accelerating Market Entry

Featured in GPE 2026 Start-Up Pavilion (Orlando), we connect with industry leaders, capital partners, and strategic allies.

Our Three Strategic Objectives:

Distribution Partnerships: Engage specialty distributors, retail networks, hobbyist leaders, and veterinary channels for Phase 1 ornamental fish commercialization.
Strategic Capital: Connect with Seed and Series A investors focused on animal health innovation, therapeutic platforms and sustainable aquaculture partners understanding regulatory pathways and platform and manufacturing scalability, and share our vision for advancing global animal health.
Market Validation: Gather field intelligence from professionals, specialists, and retail leaders to refine positioning and accelerate ABC-2 market entry timelines.

Outcome: Secure distribution partnerships, close strategic investment and manufacturing partners, and finalize market-tested go-to-market strategy, positioning for commercial launch within 18–24 months.

Meet us at GPE 2026

Page updated

Report abuse